Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Iau

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Pharmacogenetics and Genomics|June 14, 2008
Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicityLu Fan, Boon-Cher Goh, Chiung-Ing Wong, et al.
Pharmacogenetics and Genomics|October 8, 2009
Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancerSoo-Chin Lee, Xin Xu, Wee-Joo Chng, et al.
Translational Oncology|December 24, 2019
Ultrasound Guided Optoacoustic Tomography in Assessment of Tumor Margins for LumpectomiesYonggeng Goh, Ghayathri Balasundaram, Mohesh Moothanchery, et al.
Oncotarget|September 1, 2016
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancerAndrea L A Wong, Raghav Sundar, Ting-Ting Wang, et al.
Nature Genetics|October 6, 2015
Genomic landscapes of breast fibroepithelial tumorsJing Tan, Choon Kiat Ong, Weng Khong Lim, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Pharmacogenetics and Genomics|June 14, 2008
Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicityLu Fan, Boon-Cher Goh, Chiung-Ing Wong, et al.
Pharmacogenetics and Genomics|October 8, 2009
Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancerSoo-Chin Lee, Xin Xu, Wee-Joo Chng, et al.
Translational Oncology|December 24, 2019
Ultrasound Guided Optoacoustic Tomography in Assessment of Tumor Margins for LumpectomiesYonggeng Goh, Ghayathri Balasundaram, Mohesh Moothanchery, et al.
Oncotarget|September 1, 2016
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancerAndrea L A Wong, Raghav Sundar, Ting-Ting Wang, et al.
Nature Genetics|October 6, 2015
Genomic landscapes of breast fibroepithelial tumorsJing Tan, Choon Kiat Ong, Weng Khong Lim, et al.
Pageof 3